ConductScience.org, home

Paper816248

Comparative in vitro evaluation of the effects of ticarcillin and carbenicillin upon Psuedomonas aeruginosa.

Kalkani E and 1 other. Antimicrob Agents Chemother, 1976. Cited by 9 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Comparative in vitro evaluation of the effects of ticarcillin and carbenicillin upon Psuedomonas aeruginosa. Papers, record 816248. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/816248

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparative in vitro evaluation of the effects of ticarcillin and carbenicillin upon Psuedomonas aeruginosa.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1976
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.63
iCite
Revised in PubMed
2021-05-26
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kalkani EE
2Marketos NN

Source PubMed

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CarbenicillinMajor topic
PenicillinsMajor topic
Pseudomonas aeruginosaMajor topic
TicarcillinMajor topic
Penicillin Resistance

Source PubMed

References4

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14,958,434Typing of Pseudomonas pyocyanea by pyocine production.J Pathol Bacteriol1966https://conductscience.org/library/papers/4958434PubMed
24,937,796Carbenicillin therapy for pseudomonas infections.JAMA1971https://conductscience.org/library/papers/4937796PubMed
34,902,581Carbenicillin: clinical and laboratory experience with a parenterally administered penicillin for treatment of Pseudomonas infections.Ann Intern Med1969https://conductscience.org/library/papers/4902581PubMed
4806,263BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa.Antimicrob Agents Chemother1975https://conductscience.org/library/papers/806263PubMed

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
7,002,527Ticarcillin: a review of its pharmacological properties and therapeutic efficacy.Drugs1980https://conductscience.org/library/papers/7002527PubMed
417,671Comparison of ticarcillin and carbenicillin activity against random and select populations Pseudomonas aeruginosa.Antimicrob Agents Chemother1978https://conductscience.org/library/papers/417671PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/816248

GET https://conductscience.org/api/papers/v1/816248/authors